+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 99Years
All Genders
ID05000294

Study of Atezolizumab and Tivozanib for Treatment of Advanced Immunologically Cold Cancers Including Prostate, Bile Duct, Breast, Neuroendocrine, Ovarian, Pancreatic, Sarcoma, and Vulvar Cancers

Led by University of Florida · Updated on 2026-07-13

29

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of the immune checkpoint inhibitor atezolizumab and the VEGF tyrosine kinase inhibitor tivozanib to treat several immunologically cold cancers that generally respond poorly to immunotherapy alone. These cancers include prostate cancer, biliary tract cancers, soft tissue sarcomas, neuroendocrine tumors, colorectal cancer, pancreatic cancer, and certain breast cancers. The study aims to determine whether blocking VEGF can improve immune response in these tumors. Participants receive atezolizumab intravenously at a dose of 1680 mg on Day 1 of each 28-day cycle. They also take oral tivozanib daily for 21 days within each 28-day cycle. During the early phase of the study, participants receive either 1.34 mg or 0.89 mg of tivozanib per day, while in the later phase, all receive 0.89 mg daily. The study includes both phase 1B dose-finding and phase 2 evaluation stages. Participants are closely monitored through imaging and other assessments to measure tumor response, progression-free survival, overall survival, and disease control rate over 30 months. Eligibility requires advanced cancers with prior treatments or no standard options, adequate organ function, and other health criteria. The study excludes those with certain immune conditions, prior VEGF inhibitor treatments, or unstable medical issues. The participation period extends until study completion in mid-2027, with ongoing safety and efficacy evaluations.

CONDITIONS

Brief Title

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Research Team

C

Chloe Quintero

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here